AG-7404 is a potent protease inhibitor with Anti-poliovirus activity. AG-7404 was active against all virus with EC50 values ranging from 0.080 to 0.674 μM. AG-7404 was fully active against all V-073-resistant variants, with EC₅₀ values ranging from 0.218 to 0.819 μM, compared to values of 0.202-0.407 μM for the V-073-susceptible parental strains. In vitro drug combination experiments demonstrated synergy between AG-7404 and either V-073 or BTA798, whereas the combination of the two capsid inhibitors acted additively.
For research use only. We do not sell to patients.
Name | AG-7404 |
---|---|
Iupac Chemical Name | (S,E)-ethyl 4-((S)-2-(3-(5-methylisoxazole-3-carboxamido)-2-oxopyridin-1(2H)-yl)pent-4-ynamido)-5-((S)-2-oxopyrrolidin-3-yl)pent-2-enoate |
Synonyms | AG-7404; AG 7404; AG7404; V 7404; V-7404; V7404; |
Molecular Formula | C26H29N5O7 |
Molecular Weight | 523.54 |
Smile | O=C(OCC)/C=C/[C@@H](NC([C@@H](N1C=CC=C(NC(C2=NOC(C)=C2)=O)C1=O)CC#C)=O)C[C@H]3C(NCC3)=O |
InChiKey | QCUZOJBYWQPLIN-BNMFZAHFSA-N |
InChi | InChI=1S/C26H29N5O7/c1-4-7-21(31-13-6-8-19(26(31)36)29-24(34)20-14-16(3)38-30-20)25(35)28-18(9-10-22(32)37-5-2)15-17-11-12-27-23(17)33/h1,6,8-10,13-14,17-18,21H,5,7,11-12,15H2,2-3H3,(H,27,33)(H,28,35)(H,29,34)/b10-9+/t17-,18+,21-/m0/s1 |
CAS Number | 343565-99-1 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Rhoden E, Liu HM, Wang-Chern SW, Oberste MS. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination
with antiviral capsid inhibitor compounds. Antiviral Res. 2013 May;98(2):186-91. doi: 10.1016/j.antiviral.2013.03.003. Epub 2013 Mar 13. Erratum in: Antiviral Res. 2013 Sep;99(3):436. PubMed PMID: 23499651.